These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8805099)

  • 1. Different properties of wild type and drug-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase in vitro.
    Ijichi K; Fujiwara M; Shigeta S; Konno K; Yokota T; Baba M
    Microbiol Immunol; 1996; 40(5):353-8. PubMed ID: 8805099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M; Kemp SD; Parry NR; Larder BA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions of the HIV-1 reverse transcriptase 'AZT-resistant' mutant with substrates and AZT-TP.
    Pokholok DK; Gudima SO; Yesipov DS; Dobrynin VN; Rechinsky VO; Kochetkov SN
    FEBS Lett; 1993 Jul; 325(3):237-41. PubMed ID: 7686510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
    Harrigan PR; Kinghorn I; Bloor S; Kemp SD; Nájera I; Kohli A; Larder BA
    J Virol; 1996 Sep; 70(9):5930-4. PubMed ID: 8709214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors.
    Balzarini J; Weeger M; Camarasa MJ; De Clercq E; Uberla K
    Biochem Biophys Res Commun; 1995 Jun; 211(3):850-6. PubMed ID: 7541200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants.
    Kim EY; Vrang L; Oberg B; Merigan TC
    AIDS Res Hum Retroviruses; 2001 Mar; 17(5):401-7. PubMed ID: 11282008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-steady-state kinetic characterization of wild type and 3'-azido-3'-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance.
    Kerr SG; Anderson KS
    Biochemistry; 1997 Nov; 36(46):14064-70. PubMed ID: 9369478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
    Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
    Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants.
    Kleim JP; Rösner M; Winkler I; Paessens A; Kirsch R; Hsiou Y; Arnold E; Riess G
    Proc Natl Acad Sci U S A; 1996 Jan; 93(1):34-8. PubMed ID: 8552634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro selection of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine.
    Dianzani F; Antonelli G; Turriziani O; Dong G; Capobianchi MR; Riva E
    Antiviral Res; 1992 May; 18(1):39-52. PubMed ID: 1384427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
    Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.
    Johnson VA; Merrill DP; Videler JA; Chou TC; Byington RE; Eron JJ; D'Aquila RT; Hirsch MS
    J Infect Dis; 1991 Oct; 164(4):646-55. PubMed ID: 1716649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
    Larder BA; Kellam P; Kemp SD
    Nature; 1993 Sep; 365(6445):451-3. PubMed ID: 7692302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and genetical analysis of AZT-resistant HIV-mutants.
    Biesert L; Zimmermann F; Schröder B; Matthes E; Suhartono H; Dietrich U; Rübsamen-Waigmann H
    Behring Inst Mitt; 1991 Jul; (89):74-80. PubMed ID: 1930105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.
    Borkow G; Arion D; Wainberg MA; Parniak MA
    Antimicrob Agents Chemother; 1999 Feb; 43(2):259-63. PubMed ID: 9925515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase.
    Remington KM; Zhu YQ; Phillips TR; North TW
    J Virol; 1994 Feb; 68(2):632-7. PubMed ID: 7507182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication.
    Caliendo AM; Savara A; An D; DeVore K; Kaplan JC; D'Aquila RT
    J Virol; 1996 Apr; 70(4):2146-53. PubMed ID: 8642636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA.
    Kaye S; Comber E; Tenant-Flowers M; Loveday C
    AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1221-5. PubMed ID: 8573378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.